Cargando…

The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada

OBJECTIVES: We assess how different scenarios of cardiovascular disease (CVD) prevention, aimed at meeting targets set by the World Health Organization (WHO) for 2025), may impact healthcare spending in Quebec, Canada over the 2050 horizon. METHODS: We provide long-term forecasts of healthcare use a...

Descripción completa

Detalles Bibliográficos
Autores principales: Boisclair, David, Décarie, Yann, Laliberté-Auger, François, Michaud, Pierre-Carl, Vincent, Carole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754059/
https://www.ncbi.nlm.nih.gov/pubmed/29300783
http://dx.doi.org/10.1371/journal.pone.0190538
_version_ 1783290361176653824
author Boisclair, David
Décarie, Yann
Laliberté-Auger, François
Michaud, Pierre-Carl
Vincent, Carole
author_facet Boisclair, David
Décarie, Yann
Laliberté-Auger, François
Michaud, Pierre-Carl
Vincent, Carole
author_sort Boisclair, David
collection PubMed
description OBJECTIVES: We assess how different scenarios of cardiovascular disease (CVD) prevention, aimed at meeting targets set by the World Health Organization (WHO) for 2025), may impact healthcare spending in Quebec, Canada over the 2050 horizon. METHODS: We provide long-term forecasts of healthcare use and costs at the Quebec population level using a novel dynamic microsimulation model. Using both survey and administrative data, we simulate the evolution of the Quebec population’s health status until death, through a series of dynamic transitions that accounts for social and demographic characteristics associated with CVD risk factors. RESULTS: A 25% reduction in CVD mortality between 2012 and 2025 achieved through decreased incidence could contain the pace of healthcare cost growth towards 2050 by nearly 7 percentage points for consultations with a physician, and by almost 9 percentage points for hospitalizations. Over the 2012–2050 period, the present value of cost savings is projected to amount to C$13.1 billion in 2012 dollars. The years of life saved due to improved life expectancy could be worth another C$38.2 billion. Addressing CVD mortality directly instead would bring about higher healthcare costs, but would generate more value in terms of years of life saved, at C$69.6 billion. CONCLUSIONS: Potential savings associated with plausible reductions in CVD, aimed at reaching a World Health Organization target over a 12-year period, are sizeable and may help address challenges associated with an aging population.
format Online
Article
Text
id pubmed-5754059
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57540592018-01-26 The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada Boisclair, David Décarie, Yann Laliberté-Auger, François Michaud, Pierre-Carl Vincent, Carole PLoS One Research Article OBJECTIVES: We assess how different scenarios of cardiovascular disease (CVD) prevention, aimed at meeting targets set by the World Health Organization (WHO) for 2025), may impact healthcare spending in Quebec, Canada over the 2050 horizon. METHODS: We provide long-term forecasts of healthcare use and costs at the Quebec population level using a novel dynamic microsimulation model. Using both survey and administrative data, we simulate the evolution of the Quebec population’s health status until death, through a series of dynamic transitions that accounts for social and demographic characteristics associated with CVD risk factors. RESULTS: A 25% reduction in CVD mortality between 2012 and 2025 achieved through decreased incidence could contain the pace of healthcare cost growth towards 2050 by nearly 7 percentage points for consultations with a physician, and by almost 9 percentage points for hospitalizations. Over the 2012–2050 period, the present value of cost savings is projected to amount to C$13.1 billion in 2012 dollars. The years of life saved due to improved life expectancy could be worth another C$38.2 billion. Addressing CVD mortality directly instead would bring about higher healthcare costs, but would generate more value in terms of years of life saved, at C$69.6 billion. CONCLUSIONS: Potential savings associated with plausible reductions in CVD, aimed at reaching a World Health Organization target over a 12-year period, are sizeable and may help address challenges associated with an aging population. Public Library of Science 2018-01-04 /pmc/articles/PMC5754059/ /pubmed/29300783 http://dx.doi.org/10.1371/journal.pone.0190538 Text en © 2018 Boisclair et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Boisclair, David
Décarie, Yann
Laliberté-Auger, François
Michaud, Pierre-Carl
Vincent, Carole
The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada
title The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada
title_full The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada
title_fullStr The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada
title_full_unstemmed The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada
title_short The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada
title_sort economic benefits of reducing cardiovascular disease mortality in quebec, canada
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754059/
https://www.ncbi.nlm.nih.gov/pubmed/29300783
http://dx.doi.org/10.1371/journal.pone.0190538
work_keys_str_mv AT boisclairdavid theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT decarieyann theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT laliberteaugerfrancois theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT michaudpierrecarl theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT vincentcarole theeconomicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT boisclairdavid economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT decarieyann economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT laliberteaugerfrancois economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT michaudpierrecarl economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada
AT vincentcarole economicbenefitsofreducingcardiovasculardiseasemortalityinquebeccanada